Catalog No.
YHC90501
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Met1-Glu303
Predicted molecular weight
36.04 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P11802
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Cell division protein kinase 4, PSK-J3, Cyclin-dependent kinase 4, CDK4
The regulatory role of CDK4/6 inhibitors in tumor immunity and the potential value of tumor immunotherapy (Review)., PMID:40511560
Niraparib Plus Aromatase Inhibitors for Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with a Germline BRCA Mutation., PMID:40507226
Covalent Recruitment of NEDD4 for Targeted Protein Degradation: Rational Design of Small Molecular Degraders., PMID:40506832
Baseline cell cycle and immune profiles indicate CDK4/6 inhibitor response in metastatic HR + /HER2- breast cancer., PMID:40506447
BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction., PMID:40504949
Pre-existing and emerging immune-mediated diseases in patients with breast cancer undergoing cyclin-dependent kinases 4/6 inhibitors and endocrine therapy., PMID:40504547
Polystyrene microplastics induces the injury of human corneal epithelial cells through ROS-mediated p53 pathway., PMID:40503930
RBC balanced immuno-inflammatory signatures identify advanced breast cancer patients on CDK4/6 inhibitors at increased risk of progression and death., PMID:40502706
Impact of age and comorbidities on real-world outcomes in advanced breast cancer patients treated with palbociclib in first line: a nation-wide Danish retrospective study., PMID:40500959
Design and Synthesis of PARP/CDK6 Dual-Target Inhibitors Modulating of Wnt/β-Catenin Signaling Pathway for the Treatment of BRCA Wild-Type TNBC., PMID:40492684
Semisynthesis of Novel Alicyclic Triterpene-Triazole Derivatives from Boswellia sacra Gum Resin: Potential Anti-breast Cancer and Immunomodulatory Effects on T‑Cell Activation., PMID:40488047
Marine natural product Methyl mycophenolate inhibits gastric cancer growth through regulating p53 and the downstream pathways., PMID:40484944
Gilteritinib suppresses prostate cancer cell proliferation and migration and induces ER stress-mediated non-autophagic cytoplasmic vacuolization cell death., PMID:40481367
Repurposing Food and Drug Administration-approved cancer therapies: exploring endocrine and targeted pathways in low-grade serous ovarian cancer treatment., PMID:40480868
Suppression of NRAS-mutant melanoma growth with NRAS-targeting Antisense Oligonucleotide treatment reveals therapeutically relevant kinase co-dependencies., PMID:40473796
Vitiligo-Like Depigmentation Induced by Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Metastatic Breast Cancer: A Case Report and Literature Review., PMID:40470422
Clinicopathological and molecular diagnostic features of liposarcoma: A study of 27 cases., PMID:40469705
Clinicopathological features and genomics of ER-positive/HER2-negative breast cancer relapsing on adjuvant abemaciclib., PMID:40466434
Fused pyrido[3,4-D]pyrimidine moiety with phthalazinone ring accelerate dual inhibition of PARP1 and CDK4 in triple-negative breast cancer: a hybrid design with computational investigation through molecular modeling and quantum mechanics., PMID:40465091
PML1-Mediated Feedforward Loop Through PI3K and MAPK Axes Drives Endocrine Resistance., PMID:40463196
Abemaciclib-Associated Panniculitis With Fibrosis: Expanding the Dermatologic Spectrum of Cyclin-Dependent Kinase 4/6 Inhibitors., PMID:40458320
ANKHD1 promotes pathogenic proliferation in Autosomal Dominant Polycystic Kidney Disease via the Cyclin D1/CDK4 pathway., PMID:40457431
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer., PMID:40454645
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer., PMID:40454637
Key decision factors in second-line therapy: Expert insights on HR+/HER2-metastatic breast cancer post-CDK4/6 inhibitor progression., PMID:40450825
Combined therapy with DR5-targeting antibody-drug conjugate and CDK inhibitors as a strategy for advanced colorectal cancer., PMID:40449480
Dengue virus modulates critical cell cycle regulatory proteins in human megakaryocyte cells., PMID:40447783
Sarcopenia in patients with metastatic breast cancer: A systematic review and meta-analysis., PMID:40446428
RANK pathway inhibition sensitizes triple-negative breast cancer to CDK4/6 inhibitors and enhances immune response., PMID:40444791
Exploring the molecular mechanism of Si-Miao-Yong-An Decoction in treating diabetic foot using network pharmacological analysis and molecular docking technique., PMID:40441214
Updated efficacy and safety of CDK4/6 inhibitors plus endocrine therapy in elderly women with HR+/HER-2 metastatic or advanced breast cancer: patient-level network meta-analysis., PMID:40440494
Multiprotein Silencing Using WRAP-Based Nanoparticles: A Proof of Concept., PMID:40439254
Management of Metastatic Hormone Receptor-Positive Breast Cancer Beyond CDK4/6 Inhibitors., PMID:40434676
Classification of the LC4 Primarily-like Cell Line-Recapitulating a CDK4 Overexpressing Immune Evasive HIV-HCV-Induced HCC., PMID:40431665
Cyclin-Dependent Kinase 4/6 Inhibitors Combined with Radiotherapy in Curative Breast Cancer Patients Induced Pneumonitis: A Case Report., PMID:40430137
Olig1/2 Drive Astrocytic Glioblastoma Proliferation Through Transcriptional Co-Regulation of Various Cyclins., PMID:40428395
Continuing Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Advanced Breast Cancer: A Meta-Analysis., PMID:40427107
Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China., PMID:40426093
Paxilline derived from an endophytic fungus of Baphicacanthus cusia alleviates hepatocellular carcinoma through autophagy-mediated apoptosis., PMID:40425675
Pharmacokinetics, mass balance, and metabolism of [14C]FCN-437c, a selective and potent CDK4/6 inhibitor in humans., PMID:40418395
Incidence of Metastasis in the Central Nervous System in Advanced Breast Cancer Treated With CDK 4/6 Inhibitors: A Multicenter, Retrospective Study., PMID:40416598
MafB regulates hair follicle stem cell activation and hair regeneration through NFATc1 signaling pathway., PMID:40414006
A review of the efficacy of prostate cancer therapies against castration-resistant prostate cancer., PMID:40409404
Patient preferences for treatments in hormone receptor-positive/HER2-negative metastatic breast cancer in Italy: a discrete choice experiment study., PMID:40405072
Limocitrin induced cellular death through ERK pathways in human oral squamous cell cancer., PMID:40404781
A phase I dose-escalation and dose-expansion study of tibremciclib, a novel CDK4/6 inhibitor, monotherapy and in combination with fulvestrant in HR-positive/HER2-negative advanced breast cancer., PMID:40403388
Palbociclib, a Selective CDK4/6 Inhibitor, Administered Before and After Chemoradiotherapy for Human Papillomavirus-Negative, Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm, Phase II Trial., PMID:40403207
Tumor Pro-Senescence Strategy to Enhance Mild Photothermal Therapy of Diffuse Large B-Cell Lymphoma., PMID:40401540
Effect of citrus essential oil petit grain in growth and motility reduction of hypopharyngeal squamous cell carcinoma (FaDu) in vitro model., PMID:40397313
Computational analysis of DEHP's oncogenic role in colorectal cancer., PMID:40397302
For research use only. Not for human or drug use.
